Capital International Investors
PACB icon

Capital International Investors’s Pacific Biosciences PACB Stock Holding History

Capital International Investors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,113,749
Closed -$11.7M – 458
2024
Q1 		$11.7M Hold
3,113,749
– – ﹤0.01% 395
2023
Q4 		$30.5M Hold
3,113,749
– – 0.01% 358
2023
Q3 		$26M Sell
3,113,749
-1,102,052
-26% -$12.6M 0.01% 361
2023
Q2 		$56.1M Hold
4,215,801
– – 0.01% 330
2023
Q1 		$48.8M Sell
4,215,801
-1,883,880
-31% -$18.7M 0.01% 339
2022
Q4 		$49.9M Sell
6,099,681
-2,349,477
-28% -$20.2M 0.01% 327
2022
Q3 		$49M Sell
8,449,158
-3,126,338
-27% -$17.9M 0.01% 336
2022
Q2 		$51.2M Sell
11,575,496
-1,206,359
-9% -$7.33M 0.01% 345
2022
Q1 		$116M Buy
12,781,855
+675,537
+6% +$7.78M 0.03% 294
2021
Q4 		$248M Buy
12,106,318
+712,191
+6% +$17.2M 0.05% 249
2021
Q3 		$291M Buy
11,394,127
+2,616,823
+30% +$77.5M 0.07% 225
2021
Q2 		$307M Buy
8,777,304
+840,179
+11% +$24.4M 0.07% 213
2021
Q1 		$264M Sell
7,937,125
-1,870,901
-19% -$65.5M 0.07% 215
2020
Q4 		$254M Sell
9,808,026
-931,806
-9% -$15.8M 0.07% 215
2020
Q3 		$106M Buy
10,739,832
+3,943,532
+58% +$22.7M 0.03% 262
2020
Q2 		$23.4M Hold
6,796,300
– – 0.01% 346
2020
Q1 		$20.8M Buy
6,796,300
+1,514,500
+29% +$6.2M 0.01% 318
2019
Q4 		$27.1M Buy
+5,281,800
New +$26.8M 0.01% 301
2019
Q1 		– Sell
-2,080,000
Closed -$15.4M – 391
2018
Q4 		$15.4M Sell
2,080,000
-2,082,441
-50% -$13.2M 0.01% 322
2018
Q3 		$22.5M Buy
+4,162,441
New +$17.9M 0.01% 320

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors's PACB Position: Q2 2024 in Review

Capital International Investors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 3,113,749 shares — an estimated $11.7M sold.

Capital International Investors first reported a position in PACB in Q3 2018 and held it in 20 quarters. The position peaked at $307M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Capital International Investors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Capital International Investors sold 3,113,749 Pacific Biosciences shares in Q2 2024, an estimated $11.7M.
  • Capital International Investors first reported a position in Pacific Biosciences in Q3 2018 and held it in 20 quarters.
  • Capital International Investors's Pacific Biosciences position peaked at $307M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Capital International Investors's 13F filing for Q2 2024, filed 13 Aug 2024.